Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 8/2023

30-06-2023 | Minoxidil | Practical Issues and Updates

Manage androgenetic alopecia in men with established options but emerging therapies show promise

Authors: Amy Zhuang-Yan, Sheridan M. Hoy

Published in: Drugs & Therapy Perspectives | Issue 8/2023

Login to get access

Abstract

Androgenetic alopecia (AGA) is the most common type of hair loss disorder and affects both men and women. It is characterized by the progressive miniaturization of hair follicles in androgenetic areas of the scalp resulting in a decrease in hair density. While the number of options for managing AGA has increased over the years, evidence-based information and guidelines are limited. Treatments range from the approved and off-label use of pharmacological agents [including oral 5α-reductase inhibitors (e.g. dutasteride) and vasodilators (e.g. topical minoxidil)] to non-pharmacological treatments (e.g. low-level laser therapy) and emerging investigational therapies (e.g. botulinum toxin).
Literature
1.
Blume-Peytavi U, Blumeyer A, Tosti A, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol. 2011;164(1):5–15.CrossRefPubMed
2.
Saceda-Corralo D, Dominguez-Santas M, Vano-Galvan S, et al. What’s new in therapy for male androgenetic alopecia? Am J Clin Dermatol. 2023;24(1):15–24.CrossRefPubMed
3.
Manabe M, Tsuboi R, Itami S, et al. Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. J Dermatol. 2018;45(9):1031–43.CrossRefPubMed
4.
Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252–8.CrossRefPubMed
5.
Gubelin HW. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–98.CrossRef
6.
Olsen EA, Hordinksy M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014–23.CrossRefPubMed
7.
Bramson HN, Hermann D, Batchelor KW, et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282(3):1496–502.PubMed
8.
Sobhy N, Aly H, Shafee A, et al. Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males. Our Dermatol. 2013;4(1):40–5.CrossRef
9.
Saceda-Corralo D, Moustafa F, Moreno-Arrones ÓM, et al. Mesotherapy with dutasteride for androgenetic alopecia: a retrospective study in real clinical practice. J Drugs Dermatol. 2022;21(7):742–7.PubMed
10.
Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2021;164(18):2017–23.
11.
Caserini M, Radicioni M, Leuratti C, et al. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19–27.CrossRefPubMed
12.
Caserini M, Radicioni M, Leuratti C, et al. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842–9.CrossRefPubMed
13.
Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95(10):1312–6.PubMed
14.
Chandrashekar B, Nandhini T, Vasanth V, et al. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17.CrossRefPubMedPubMedCentral
15.
Freund BJ, Schwartz M. Treatment of male pattern baldness with botulinum toxin: a pilot study. Plast Reconstr Surg. 2010;126(5):246–8.CrossRef
16.
Singh S, Neema S, Vasudevan B. A pilot study to evaluate effectiveness of botulinum toxin in treatment of androgenetic alopecia in males. J Cutan Aesthet Surg. 2017;10(3):163.CrossRefPubMedPubMedCentral
17.
Bharti J, Sonthalia S, Patil P, et al. Scalp threading with polydioxanone monofilament threads: a novel, effective and safe modality for hair restoration. J Eur Acad Dermatol Venereol. 2017;31(11):e492–3.CrossRefPubMed
Metadata
Title
Manage androgenetic alopecia in men with established options but emerging therapies show promise
Authors
Amy Zhuang-Yan
Sheridan M. Hoy
Publication date
30-06-2023
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 8/2023
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-023-01011-2

Other articles of this Issue 8/2023

Drugs & Therapy Perspectives 8/2023 Go to the issue

Adis Drug Q&A

Dextromethorphan/bupropion in major depressive disorder: a profile of its use

Practical Issues and Updates

Screen for drug-induced gambling disorder in vulnerable patients receiving dopaminergic drugs

Disease Management

Manage early morning ADHD symptoms and functional impairment with treatments that are effective from awakening

Adis Drug Q&A

Oteseconazole in recurrent vulvovaginal candidiasis: a profile of its use

Adis Drug Q&A

Desidustat in anaemia in patients with chronic kidney disease: a profile of its use